SAN FRANCISCO, Feb. 28, 2025 /PRNewswire/ — Novo Nordisk A/S (NYSE: NVO) is embroiled in a class-action lawsuit filed by investors who claim they were misled about the future of its experimental obesity treatment, CagriSema. Hagens Berman urges investors who purchased Novo Nordisk shares…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.